Stocksigma LogoStocksigma Logo

Gufic Biosciences Reports Robust Q2 FY27 Financial and Operational Performance

Gufic Biosciences posted a total revenue of Rs 288.4 cr in Q2 FY27, up 25.17% YoY from Rs 230.4 cr in Q2 FY26 and 10.58% QoQ

Gufic Biosciences Reports Robust Q2 FY27 Financial and Operational Performance

Gufic Biosciences Ltd 路 Investor Presentation 路 15 Nov 2026, 2:04 am

Gufic Biosciences Reports Robust Q2 FY27 Financial and Operational Performance Gufic Biosciences posted a total revenue of Rs 288.4 cr in Q2 FY27, up 25.17% YoY from Rs 230.4 cr in Q2 FY26 and 10.58% QoQ. EBITDA reached Rs 49.7 cr with a 17.23% margin, while PAT stood at Rs 23.5 cr (8.15% margin), rising 57.72% YoY. For H1 FY27, total income reached Rs 550.8 cr with PAT of Rs 46.0 cr. Operationally, the US FDA completed a pre-approval inspection at its Indore facility with three observations being addressed, while EU GMP certification remains awaited.

Original exchange filing (PDF)

More announcements from Gufic Biosciences Ltd

All Gufic Biosciences Ltd announcements